DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer

Clinical trial NCT05680922 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05680922
Sponsor: Legend Biotech USA Inc
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Small Cell Lung Cancer Extensive Stage Large Cell Neuroendocrine Carcinoma of the Lung

Start date: 2023-07-26
Primary completion: 2027-12-01
Enrollment: 41

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.